Literature DB >> 7606897

Immunohistochemical study of giant cell in glioblastoma.

H Kawano1, T Kubota, K Sato, T Goya, S Arikawa, S Wakisaka.   

Abstract

The clinical and immunohistochemical features of supratentorial (5 patients) and cerebellar (1 patient) glioblastomas, in which giant cells were conspicuous were examined. Three of the patients died within 26 months after the first treatment, and the follow-up period is presently 1 year or less in the remaining patients. The giant cells either showed large and bizarre nuclei or were multinucleated. Both giant and smaller cells excluding neuronal, endothelial and infiltrative cells were positive for GFAP, vimentin, and alpha-1 anti-chymotrypsin. The strong positivity for PCNA staining indicated that the capacity of the giant cells to synthesis DNA was preserved. DNA fragmentation, measured by the terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine-5'-triphosphate (dUTP)-biotin nick end labeling method, was observed in only 1 patient, who had received radiotherapy just before biopsy, and none of the patients showed bcl-2 positivity. Mutant type of p53 tumor suppressor gene was observed in the giant cells of 3 patients. Giant cell in glioblastoma is of glial origin, synthesizes DNA, and its progression may be related to tumor suppressor gene.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7606897

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  9 in total

1.  Magnetic resonance imaging and computed tomography findings in pediatric giant cell glioblastoma.

Authors:  L Zipp; K M Schwartz; E Hewer; Y Yu; C Stippich; J M Slopis
Journal:  Clin Neuroradiol       Date:  2012-12       Impact factor: 3.649

2.  Formation of solid tumors by a single multinucleated cancer cell.

Authors:  Zhang Weihua; Qingtang Lin; Asa J Ramoth; Dominic Fan; Isaiah J Fidler
Journal:  Cancer       Date:  2011-03-01       Impact factor: 6.860

3.  Mitotic activity of multinucleated giant cells with glial fibrillary acidic protein immunoreactivity in glioblastomas: an immunohistochemical double labeling study.

Authors:  Hiroaki Takeuchi; Kazufumi Sato; Kazunori Ido; Toshihiko Kubota
Journal:  J Neurooncol       Date:  2006-04-25       Impact factor: 4.130

4.  Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis.

Authors:  Kevin R Kozak; John S Moody
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

5.  Giant cell glioblastoma with spinal and spinal leptomeningeal metastasis in a child: A rare presentation of a rare tumor.

Authors:  Rituparna Biswas; Subhash Gupta; K P Haresh; Anirban Halder; G K Rath
Journal:  J Craniovertebr Junction Spine       Date:  2018 Jul-Sep

6.  Association between giant cell glioblastoma and glioblastoma multiforme in the United States: A retrospective cohort study.

Authors:  Amro K Bin Abdulrahman; Khalid A Bin Abdulrahman; Yousef R Bukhari; Abdulaziz M Faqihi; Juan Gabriel Ruiz
Journal:  Brain Behav       Date:  2019-08-29       Impact factor: 2.708

7.  Giant cell glioblastoma in the pediatric age group: Report of two cases.

Authors:  Sachin Anil Borkar; G Lakshmiprasad; Kiran Chikkanahalli Subbarao; Mehar Chand Sharma; Ashok K Mahapatra
Journal:  J Pediatr Neurosci       Date:  2013-01

8.  Molecular features unique to glioblastoma radiation resistant residual cells may affect patient outcome - a short report.

Authors:  Ekjot Kaur; Jayant S Goda; Atanu Ghorai; Sameer Salunkhe; Prakash Shetty; Aliasgar V Moiyadi; Epari Sridhar; Abhishek Mahajan; Rakesh Jalali; Shilpee Dutt
Journal:  Cell Oncol (Dordr)       Date:  2018-10-26       Impact factor: 7.051

9.  Loss of TRPV2 Homeostatic Control of Cell Proliferation Drives Tumor Progression.

Authors:  Sonia Liberati; Maria Beatrice Morelli; Consuelo Amantini; Valerio Farfariello; Matteo Santoni; Alessandro Conti; Massimo Nabissi; Stefano Cascinu; Giorgio Santoni
Journal:  Cells       Date:  2014-02-19       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.